EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders

Marc Ferrer, Vanesa Richarte, Laura Gisbert, Jordi Xaus iD, Sonia Gutierrez, Maria Isabel Arevalo, Michael Ropacki, Roger Bullock, Carlos Buesa, Josep Antoni Ramos-Quiroga

Psychiatry and Clinical Neurosciences · 2025

DOI: 10.1111/pcn.13800 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Psychiatry and Clinical Neurosciences, 2025. Verfasst von Marc Ferrer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Aggression, Borderline Personality Disorder, Attention Deficit Disorder with Hyperactivity, Autism Spectrum Disorder. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oryzon Genomics SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Vafidemstat is a brain‐penetrant, orally bioavailable, small molecule irreversible inhibitor of the histone lysine‐specific demethylase KDM1A (also known as LSD1), which corrects memory deficits and behavior alterations including aggression and social interaction deficits in preclinical models.

Methods

Here, we report the results of REIMAGINE, a phase IIa, single‐center, open‐label, one‐arm basket trial that evaluated the safety and efficacy of vafidemstat on aggression in adult patients with borderline personality disorder (BPD), attention‐deficit/hyperactivity disorder (ADHD), and autistic spectrum disorder (ASD). Participants received 1.2 mg/day of vafidemstat for 8 weeks.

Results

Vafidemstat was shown to be safe and well tolerated, and no drug‐related clinically significant adverse events were observed. Furthermore, all neuropsychiatric scales assessed showed notable efficacy signals, whether assessing agitation/aggression (Clinical Global Impression for Severity [CGI‐S] and Clinical Global Impression for Improvement [CGI‐I] and Neuropsychiatric Inventory [NPI] questionnaire for Agitation‐Aggression [NPI‐AA]), overall patient functioning (total NPI), or disease‐specific features (Attention‐Deficit/Hyperactivity Disorder Rating Scale [ADHD‐RS] and Borderline Personality Disorder Checklist [BPDCL]). Statistically significant improvements were observed in the aggregated data (all participants) and for each of the three disease groups independently. Changes were evident within the first 2 weeks of treatment.

Conclusion

In summary, the REIMAGINE study supports that vafidemstat is safe, well tolerated, and causes a significant and consistent reduction in agitation/aggression and nonaggression features in BPD, ADHD, and ASD. These data support continuing the development of vafidemstat as a new treatment option for these psychiatric disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AggressionBorderline Personality DisorderAttention Deficit Disorder with HyperactivityAutism Spectrum DisorderOutcome Assessment, Health CareHumansAdultMaleFemaleMiddle AgedYoung AdultAdolescent

Stichwörter der Autor:innen

aggressionattention‐deficit/hyperactivity disorderautistic spectrum disorderborderline personality disordervafidemstat

Autor:innen und Institutionen

  • Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Oryzon Genomics S.A. Cornellà de Llobregat, Barcelona, Spain.

ORCID-Profile: Jordi Xaus

Förderung

  • Oryzon Genomics SA

Zitieren

APA

Ferrer, M., Richarte, V., Gisbert, L., Xaus, J., Gutierrez, S., Arevalo, M. I., Ropacki, M., Bullock, R., Buesa, C., & Ramos-Quiroga, J. A. (2025). REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13800

Vancouver

Ferrer M, Richarte V, Gisbert L, Xaus J, Gutierrez S, Arevalo MI, et al. REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders. Psychiatry and Clinical Neurosciences. 2025. doi:10.1111/pcn.13800

BibTeX
@article{Ferrer2025,
  author = {Ferrer, Marc and Richarte, Vanesa and Gisbert, Laura and Xaus, Jordi and Gutierrez, Sonia and Arevalo, Maria Isabel and Ropacki, Michael and Bullock, Roger and Buesa, Carlos and Ramos-Quiroga, Josep Antoni},
  title = {REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2025},
  doi = {10.1111/pcn.13800}
}
Kostenlos starten →